mPatient Myeloma Radio: Dr. Jay Bradner, MD, Dana Farber Cancer Institute

Join us as we talk with Dr. Jay Bradner, MD of the Bradner Lab, Dana Farber Cancer Institute and Harvard Medical School. Dr. Bradner focuses his research on the use of chemical biology to target gene regulatory pathways. Specifically, Dr. Bradner is working to develop a MYC inhibitor for myeloma. MYC is the most common translocation to be found in multiple myeloma and increases in prevalance as the disease progresses, so finding a target for this translocations is critical.